Chamath Palihapitiya is still all in on SPACs.
The venture capitalist-turned-SPAC-enthusiast filed on Wednesday to raise four more special purpose acquisition companies with a new partner. They add to the six blank-check companies Palihapitiya has already raised. He’s said he plans to set up 26 SPACs and name them alphabetically.
The latest are a partnership between Palihapitiya’s Social Capital and Suvretta Capital Management, an investment firm with an arm that focuses on the health-care industry, according to filings with the U.S. Securities and Exchange Commission.
They are called Social Capital Suvretta Holdings Corp. I, II, II and IV. Palihapitiya is their chief executive officer and their president is Kishan Mehta, who overseas the health-care strategy at Suvretta. Each vehicle is seeking $200 million and has a focus in a different health-care sector: neurology, oncology, organ and immunology.
“Our company unites scientists, physicians, entrepreneurs and biotechnology-oriented investors around a shared vision of identifying and investing in innovative and agile biotechnology companies,” Social Capital Suvretta said.
Suvretta, an investment firm founded by former SAC Capital chief investment officer Aaron Cowen, has a division focused on health-care called Averill.
The SPACs are expected to trade on the Nasdaq under the symbols DNAA, DNAB, DBAC and DNAD. Morgan Stanley is lead adviser on the listings. Credit Suisse Group AG had been on all of Social Capital’s previous SPAC listings.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU